Skip to content

Study · Not a test of the peptide alone · 2006

2 results

Rigid linkers for bioactive peptides.

Vagner J, Handl HL, Monguchi Y, Jana U, Begay LJ, Mash EA, Hruby VJ, Gillies RJ

Bioconjugate chemistry1 Nov 2006Cited by 24 (Europe PMC)

PMID17105235 (opens in a new tab)PMCIDPMC2743982 (opens in a new tab)DOI10.1021/bc060154p (opens in a new tab)PepBankPUB-17105235
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In control experiments, rigid linkers had little or no effect on NDP-alpha-MSH or MSH(4) binding to the human melanocortin 4 receptor.

    In plain wordsIn lab tests, the linkers had little or no effect on how NDP-alpha-MSH bound its receptor.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeEffect of linkers on NDP-alpha-MSH binding to hMC4R
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Control experiments indicate there is little or no effect of these linkers on NDP-alpha-MSH or MSH(4) binding to the human melanocortin 4 receptor (hMC4R).
    1 context sentence
    Summary · context
    Rigid linkers of variable length were used to connect two high-affinity Nle4-D-Phe7-alpha-melanocyte stimulating hormone (NDP-alpha-MSH) or two low-affinity MSH(4) ligands.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    Tethering two high-affinity NDP-alpha-MSH ligands with rigid linkers gave no binding enhancement.

    In plain wordsIn lab tests, joining two NDP-alpha-MSH molecules with linkers did not improve receptor binding.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeBinding of two tethered high-affinity NDP-alpha-MSH ligands
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Tethering two high-affinity ligands gave no binding enhancement
    1 context sentence
    Summary · context
    Rigid linkers of variable length were used to connect two high-affinity Nle4-D-Phe7-alpha-melanocyte stimulating hormone (NDP-alpha-MSH) or two low-affinity MSH(4) ligands.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.